[A trial of the use of diflucan (fluconazole) in patients with vaginal candidiasis].
Fifty females with vaginitis due to Candida albicans were treated with fluconazol (diflucan) in a single dose of 150 mg administered per os. A complete elimination of the clinical signs in 42 out of 50 patients (84 per cent) and a significant improvement of the clinical picture in 4 out of 50 patients (8 per cent) were recorded. The cultures of the smears produced no fungal growth with respect to 31 out of 36 patients (86.1 per cent), while microscopically the presence of the fungus with the signs of pathomorphosis was detected. Such cells could be a source of the fungal reinfection. Therefore, diflucan proved to be a highly efficient drug in the treatment of vaginal candidiasis and might be considered as an additional agent for the therapy of the disease.
Dmitrieva
N V
NV
Sokolova
E N
EN
Makhova
E E
EE
Petukhova
I N
IN
D000284:Administration, Oral; D000328:Adult; D002176:Candida albicans / Q000302:isolation & purification; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006194:Gardnerella vaginalis / Q000302:isolation & purification; D006801:Humans; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D014626:Vaginal Smears
D015725:Fluconazole
Opyt primeneniia difliukana (fliukonazol) u bol'nykh vaginal'nym kandidozom.